Influence of anti-androgen therapy for prostatic hypertrophy on lipid metabolism
Antiandrogen therapy has an important role in the treatment of patients with benign prostatic hypertrophy who lack indication for surgery. Herein, the effects on lipid metabolism of administration of antiandrogen agents for benign prostatic hypertrophy are reported. Eighty patients with benign prost...
| Veröffentlicht in: | Hinyokika kiyo. Acta urologica Japonica. - 1962. - 40(1994), 3 vom: 15. März, Seite 215-9 |
|---|---|
| 1. Verfasser: | |
| Weitere Verfasser: | , , |
| Format: | Aufsatz |
| Sprache: | Japanese |
| Veröffentlicht: |
1994
|
| Zugriff auf das übergeordnete Werk: | Hinyokika kiyo. Acta urologica Japonica |
| Schlagworte: | English Abstract Journal Article Androgen Antagonists Lipids Lipoproteins, HDL Chlormadinone Acetate 0SY050L61N Malondialdehyde 4Y8F71G49Q Nandrolone mehr... |
| Zusammenfassung: | Antiandrogen therapy has an important role in the treatment of patients with benign prostatic hypertrophy who lack indication for surgery. Herein, the effects on lipid metabolism of administration of antiandrogen agents for benign prostatic hypertrophy are reported. Eighty patients with benign prostatic hypertrophy were each treated with the antiandrogen agents, chlormadinone acetate, allylestrenol, gestonolone caproate and oxendolone for 12 months. The levels of total cholesterol (TC), triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), alpha-lipoprotein, apoprotein, and maronediardehyde (MDA) were measured every 4 weeks after initiation of antiandrogen treatment. In the chlormadinone acetate group, the TG level was significantly decreased between 3 and 6 months after treatment (p < 0.05). In the oxendolone group, the alpha-lipoprotein level was also elevated between 3 and 6 months and between 6 to 12 months after treatment (p < 0.05). The MDA level was also significantly elevated 6 and 12 months after treatment. However, the levels of the other lipids were within the normal range. In conclusion, the changes in the levels of plasma lipoprotein, apoprotein and MDA resulting from antiandrogen therapy were unlikely to be a cause of ischemic coronary disease |
|---|---|
| Beschreibung: | Date Completed 03.06.1994 Date Revised 19.11.2015 published: Print Citation Status MEDLINE |
| ISSN: | 0018-1994 |